{"gene":"SASH1","run_date":"2026-06-10T07:46:29","timeline":{"discoveries":[{"year":2003,"finding":"SASH1 encodes a member of the SH3/SAM adapter molecule family, with protein domain analysis revealing SH3 and SAM domains, suggesting a role in signaling pathways. Two transcripts (~4.4 and ~7.5 kb) were identified.","method":"In silico domain analysis, EST/genomic sequence comparison, Northern blot","journal":"Oncogene","confidence":"Low","confidence_rationale":"Tier 4 / Weak — domain-based inference only, no direct functional experiment on protein mechanism","pmids":["12771949"],"is_preprint":false},{"year":2011,"finding":"SASH1 localizes to the nucleus, cytoplasm, lamellipodia, and membrane ruffles in epithelial cells, where it co-distributes with the actin cytoskeleton. SASH1 interacts with cortactin (an actin polymerization regulator). Overexpression increases filamentous actin content and cell protrusions; this activity maps to the central conserved domain. SASH1 overexpression inhibits cell migration and increases adhesion to fibronectin and laminin, while knockdown reduces cell-matrix adhesion.","method":"Immunofluorescence/co-localization, structural domain mutants, F-actin staining, migration assays, adhesion assays, siRNA knockdown","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple orthogonal methods (localization, co-distribution, domain mapping, functional assays), single lab","pmids":["21820526"],"is_preprint":false},{"year":2013,"finding":"SASH1 acts as a scaffold protein in TLR4 signaling in endothelial cells, independently binding TRAF6, TAK1, IκB kinase α, and IκB kinase β. This interaction fosters ubiquitination of TRAF6 and TAK1 and promotes LPS-induced NF-κB, JNK, and p38 activation, increasing proinflammatory cytokine production and LPS-induced endothelial migration.","method":"Co-immunoprecipitation, ubiquitination assays, LPS stimulation, NF-κB/JNK/p38 pathway assays, cytokine measurements, migration assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying multiple binding partners, ubiquitination assays, multiple downstream pathway readouts, functional phenotype","pmids":["23776175"],"is_preprint":false},{"year":2013,"finding":"SASH1 mutations associated with dyschromatosis cause increased melanocyte migration. Mutated SASH1 shows intensified binding with IQGAP1 and Gαs, and induces uniform loss of E-Cadherin in A375 cells, suggesting SASH1 regulates IQGAP1-E-Cadherin signaling and acts as a scaffold linking GPCR/calmodulin signaling to melanocyte invasion.","method":"Patient mutation identification, functional cell migration assays, co-immunoprecipitation (IQGAP1, Gαs binding), Western blot (E-Cadherin)","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP of binding partners, functional migration assay, single lab with multiple methods","pmids":["23333244"],"is_preprint":false},{"year":2016,"finding":"SASH1 is cleaved by caspase-3 following UVC-induced apoptosis. The C-terminal cleavage fragment (aa 231–1247) translocates from the cytoplasm to the nucleus and associates with chromatin. Overexpression of wild-type or cleaved SASH1 increases apoptosis; mutation of the cleavage site inhibits nuclear translocation and prevents apoptosis initiation. SASH1 cleavage is required for efficient nuclear translocation of NF-κB, and the effect of SASH1 on apoptosis is NF-κB-dependent (demonstrated by DHMEQ inhibitor).","method":"Caspase cleavage assays, UVC treatment, subcellular fractionation/immunofluorescence (nuclear translocation), site-directed mutagenesis of cleavage site, apoptosis assays, NF-κB inhibitor (DHMEQ)","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro cleavage assay, mutagenesis of cleavage site with functional consequence, subcellular localization, pharmacological inhibitor validation, multiple orthogonal methods","pmids":["27831555"],"is_preprint":false},{"year":2016,"finding":"SASH1 is regulated by a p53/POMC/α-MSH/Gαs/SASH1 cascade mediating melanogenesis. A novel p53/POMC/Gαs/SASH1 autoregulatory positive feedback loop is activated by SASH1 mutations to induce pathological hyperpigmentation. SASH1 is physiologically induced by p53 upon UV stimulation, and SASH1 and p53 are reciprocally induced.","method":"Reporter assays, Western blot, UV stimulation experiments, patient mutation analysis, pathway activation assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pathway activation experiments with multiple components, single lab, mechanistic follow-up limited to abstract description","pmids":["27885802"],"is_preprint":false},{"year":2017,"finding":"SASH1 overexpression suppresses Shh and downstream Gli1, Smo, Ptc signaling in hepatocarcinoma cells, inhibiting proliferation and invasion. This effect was reversed by Shh pathway agonist purmorphamine or PI3K/Akt agonists (740Y-P, PDGF), placing SASH1 upstream of Shh-Gli1 and PI3K/Akt pathways to inhibit invasion and metastasis in vivo and in vitro.","method":"Western blot, qRT-PCR, Transwell assay, pharmacological agonist rescue (purmorphamine, 740Y-P, PDGF), orthotopic xenograft mouse model","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via pharmacological rescue in vitro and in vivo, multiple pathway readouts, single lab","pmids":["28600143"],"is_preprint":false},{"year":2017,"finding":"SASH1 is critical for lumen formation in a 3D breast cancer model. SASH1 RNAi inhibits lumen formation downstream of CEACAM1. SASH1 acts through DLK1 (a NOTCH1 inhibitor) to regulate NOTCH1 signaling; SASH1 RNAi down-regulates DLK1, and DLK1 RNAi also inhibits lumen formation. NOTCH1 and its target genes HES1 and HEY1 are up-regulated by SASH1 RNAi and down-regulated by DLK1 RNAi, placing SASH1 upstream of DLK1-NOTCH1 in lumenogenesis.","method":"RNAi knockdown, 3D culture lumen formation assay, gene array, epistasis (DLK1 RNAi, γ-secretase inhibitor)","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via RNAi and pharmacological inhibition, functional 3D assay, single lab","pmids":["28823832"],"is_preprint":false},{"year":2018,"finding":"SASH1 interacts with the oncoprotein CRKL (identified by yeast 2-hybrid and co-immunoprecipitation/mass spectrometry, confirmed by domain mapping, site-directed mutagenesis, and dynamic mass redistribution assays). SASH1 inhibits CRKL-mediated activation of SRC kinase, which is required for EMT. SASH1-deficient colon cancer cells undergo EMT and form more metastases in vivo; these effects depend entirely on CRKL.","method":"Yeast 2-hybrid, co-immunoprecipitation/mass spectrometry, domain mapping, site-directed mutagenesis, dynamic mass redistribution assay, CRISPR/Cas9 knockout, RNAi, EMT assays, orthotopic mouse metastasis model","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Y2H, Co-IP/MS, mutagenesis, dynamic mass redistribution), in vivo epistasis, single lab with rigorous controls","pmids":["30480076"],"is_preprint":false},{"year":2019,"finding":"Endothelial Sash1 interacts with β-arrestin 1 downstream of the TLR4 pathway to activate Akt and endothelial nitric oxide synthase (eNOS) in microvascular endothelial cells. Nitric oxide generated downstream of Sash1 in endothelial cells affects alveolar epithelial cells in a cGMP-dependent manner, inducing maturation of alveolar type 1 and 2 cells and promoting pulmonary surfactant production. Sash1-/- mice die perinatally from respiratory distress due to delayed alveolar epithelial maturation.","method":"Sash1 knockout mouse generation, endothelial-restricted conditional knockout, co-immunoprecipitation (β-arrestin 1), eNOS/Akt activity assays, cGMP pathway assays, surfactant protein measurement, histology","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic knockout with defined phenotype, Co-IP identifying binding partner, biochemical pathway assays (eNOS, Akt, cGMP), cell-nonautonomous mechanism validated in vivo","pmids":["31067462"],"is_preprint":false},{"year":2019,"finding":"HMGB1 contributes to methylation of SASH1 gene CpG islands (demonstrated by ChIP assay showing HMGB1 binding to SASH1 CpG islands); HMGB1 overexpression in astrocytes increases SASH1 methylation level. Reduced SASH1 expression in turn decreases integrin β8 expression, reducing cell adhesion and promoting migration.","method":"Methylation assay, ChIP assay (HMGB1 binding to SASH1 CpG islands), HMGB1 overexpression, integrin β8 Western blot, adhesion/invasion assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP identifies HMGB1 as writer of SASH1 methylation, downstream integrin β8 effect shown by Western blot, single lab","pmids":["31138780"],"is_preprint":false},{"year":2020,"finding":"SASH1 knockdown in TNBC cells downregulates phosphorylation of LATS1 and its effector YAP, leading to YAP accumulation and upregulation of CYR61. SASH1-induced YAP regulation is LATS1-dependent; in reverse, LATS1 phosphorylates SASH1 at S407. The phosphorylation-deficient SASH1 S407A mutant fails to rescue altered YAP signaling. SASH1 depletion upregulates ARHGAP42 via YAP-TEAD, and the YAP-ARHGAP42-actin axis drives SASH1-regulated TNBC cell invasion.","method":"siRNA knockdown, SASH1 overexpression, phospho-Western blot (LATS1, YAP), CYR61 assay, YAP pharmacological inhibitor and siRNA epistasis, S407A mutagenesis, ARHGAP42 knockdown, chicken CAM and mouse xenograft models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — phosphorylation site mutagenesis with functional rescue, epistasis via multiple knockdown approaches and pharmacological inhibitor, in vivo validation, multiple orthogonal methods","pmids":["32523092"],"is_preprint":false},{"year":2020,"finding":"SASH1 co-localizes with linear adherens junctions (AJs) and circumferential actin bundles in normal epithelial cells. SASH1 depletion by RNAi in IAR-20 cells destroys stable linear AJs and induces acquisition of mesenchymal phenotype, demonstrating SASH1's role in maintaining stable cell-cell adhesion.","method":"Immunofluorescence, confocal microscopy, RNAi knockdown, EMT assay","journal":"Biochemistry. Biokhimiia","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization and loss-of-function with specific structural phenotype (AJ disruption), single lab","pmids":["32586229"],"is_preprint":false},{"year":2020,"finding":"Mutated SASH1 (Y551D) knock-in mice show increased expression of Mitf (microphthalmia-associated transcription factor) in tail epithelium and increased Mitf-positive epithelial cells, recapitulating DUH hyperpigmentation. SASH1 may function as a scaffold to assemble a SASH1-Mitf molecular complex regulating Mitf expression in the nucleus.","method":"Heterozygous SASH1 knock-in mouse model (Y551D), immunohistochemistry, in vitro cell assays","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo knock-in model with defined molecular phenotype (Mitf upregulation), corroborated in vitro, single lab","pmids":["32582980"],"is_preprint":false},{"year":2020,"finding":"SASH1 mutations (identified in DUH families) downregulate THBS1 (thrombospondin 1) expression and inactivate TGF-β1 signaling, promoting melanocyte migration and invasion. TGF-β1 expressed by melanocytes negatively regulates SASH1 protein expression, establishing a reciprocal regulatory relationship.","method":"Patient mutation identification, bioinformatics (THBS1 pathway), Transwell/wound-healing migration assays, Western blot (TGF-β1, SASH1), melanin content measurement","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional cell assays with pathway context, single lab, mechanistic detail limited in abstract","pmids":["32174800"],"is_preprint":false},{"year":2022,"finding":"The SAM1 domain of SASH1 exists primarily as a disordered monomer with a minor oligomer in solution, unlike the dimeric SAM domain of the related SASH3. NMR and SEC-MALS characterization revealed multiple timescale exchange regimes. D663A/T664K substitutions in SAM1 increased oligomerization, identifying a region important for oligomerization.","method":"SEC-MALS, HPLC, NMR (assignment, relaxation, exchange experiments), site-directed mutagenesis (D663A/T664K), SE-HPLC","journal":"Journal of structural biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biophysical structural characterization with NMR and SEC-MALS, mutagenesis validating oligomerization region, single lab with multiple orthogonal techniques","pmids":["36341956"],"is_preprint":false},{"year":2022,"finding":"SASH1 knockdown in hemangioma endothelial cells (HemECs) suppresses TRAF6 ubiquitination, leading to destabilization and reduced expression of EZH2. Co-immunoprecipitation confirmed regulation of TRAF6 and EZH2 ubiquitination by SASH1. EZH2 overexpression reversed the anti-proliferative and pro-apoptotic effects of SASH1 knockdown.","method":"Co-immunoprecipitation, ubiquitination assay, CCK-8/cell cycle/apoptosis assays, wound healing/Transwell assays, EZH2 overexpression rescue","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitination assays establish mechanistic link, rescue experiment with EZH2 overexpression, single lab","pmids":["35772492"],"is_preprint":false},{"year":2023,"finding":"SASH1 is a novel binding partner of Eph receptors, interacting via SAM-SAM domain interactions. SASH1 selectively interacts with Eph receptors through its SAM1 domain, with highest affinity for EphA8. The crystal structure of the EphA8-SASH1 complex revealed specific intermolecular interactions. EphA8 and SASH1 co-localize and co-precipitate in mammalian cells. Cancer mutations (EphA8 R942H or G978D) impair this interaction. SAM-SAM interaction is critical for SASH1-mediated regulation of EphA8 kinase activity.","method":"Crystal structure determination, biochemical binding assays, co-immunoprecipitation, co-localization assays in mammalian cells, cancer mutation analysis, kinase activity assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of complex plus biochemical assays plus cellular co-IP plus functional kinase activity assay, multiple orthogonal methods","pmids":["37619706"],"is_preprint":false},{"year":2023,"finding":"HMGB1 forms a physical complex with SET and HAT1 in lung adenocarcinoma cells (HMGB1/SET/HAT1 complex), inhibiting H3K9 and H3K27 acetylation at the SASH1 locus, thereby suppressing SASH1 expression and facilitating glycolysis and metastasis.","method":"Co-immunoprecipitation (HMGB1/SET/HAT1 complex), ChIP (H3K9ace, H3K27ace), Western blot, in vitro and in vivo tumor models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifies complex, ChIP shows histone modification changes at SASH1 locus, single lab","pmids":["37794134"],"is_preprint":false},{"year":2023,"finding":"SASH1 interacts with Caskin1/2 via SAM-SAM domain interactions (SASH1 SAM1 domain). This interaction disrupts the Caskin1 tandem SAM homopolymer. Key residues at the end-helix/mid-loop interface mediate this interaction. Structural insights were provided by AlphaFold2-predicted models validated by mutagenesis.","method":"Yeast 2-hybrid screening, SEC, ITC, GST pull-down, co-immunoprecipitation, AlphaFold2 structural modeling, mutagenesis, sedimentation assay, TEM, immunofluorescence","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods (Y2H, ITC, GST pulldown, Co-IP), structural modeling with mutagenesis validation, polymer disruption demonstrated by sedimentation/TEM/IF","pmids":["39688081"],"is_preprint":false},{"year":2024,"finding":"LATS2 phosphorylates SASH1, forming a MAP4K4-LATS2-SASH1-YAP1 cascade in luminal breast cancer. MAP4K4 negatively regulates LATS2, SASH1, and YAP1 expression and YAP1 phosphorylation. Combined MAP4K4 overexpression and SASH1 silencing promote YAP1 dephosphorylation, YAP1/TAZ nuclear translocation, and downstream transcriptional regulation.","method":"Overexpression and siRNA knockdown, phosphorylation assays (LATS2 kinase assay on SASH1), Western blot, nuclear fractionation, in vitro and in vivo tumor models","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase phosphorylation assay establishing LATS2→SASH1 modification, epistasis cascade with multiple components, in vivo validation, single lab","pmids":["38657867"],"is_preprint":false},{"year":2023,"finding":"SASH1 promotes stem-like characteristics in human melanocytes, and interacts with tankyrase 2 (TNKS2). Multiple assays confirmed SASH1-TNKS2 binding; the SASH1 S519N variant is located in a bona fide tankyrase-binding motif and alters the binding kinetics and affinity of the interaction, impairing SASH1's role in melanocyte stem cell maintenance.","method":"Yeast 2-hybrid screening, biochemical binding assays (binding kinetics/affinity), cell-based stem cell assays, SASH1 S519N variant functional analysis","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Y2H plus binding kinetics assays, functional cell assay, preprint status lowers confidence","pmids":["37808724"],"is_preprint":true},{"year":2024,"finding":"SASH1 interacts with TNKS2 (tankyrase 2) via a tankyrase-binding motif; the S519N variant alters binding kinetics and affinity. SASH1 regulates melanocyte stem cell (McSC) maintenance, and this function is TNKS2-dependent. SASH1 S519N is defective in promoting stem-like function.","method":"Yeast 2-hybrid screening, biochemical binding affinity assays, clinical examination, human cell assays","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Y2H and biochemical binding assays confirming TNKS2 as SASH1 partner, functional stem cell assay, single lab, peer-reviewed replication of preprint","pmids":["38848986"],"is_preprint":false},{"year":2025,"finding":"SASH1 suppresses TGF-β1 signaling through regulation of THBS1. SASH1 knockdown increases TGF-β1 levels, but THBS1 counteracts this increase. SASH1 inhibits proliferation, migration, invasion, EMT, and promotes melanin synthesis through TGF-β1/THBS1 signaling. In vivo, SASH1 knockdown A375 cells show enhanced tumor growth.","method":"SASH1/THBS1 modulation by siRNA/overexpression, Western blot/qPCR (SASH1/THBS1/TGF-β1 pathway), cell phenotype assays, melanin synthesis measurement, in vivo xenograft","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — genetic epistasis (SASH1→THBS1→TGF-β1) with rescue experiments, in vivo confirmation, single lab","pmids":["41284354"],"is_preprint":false},{"year":2026,"finding":"SASH1 interacts with PKM2 in astrocytes; SASH1 depletion causes increased nuclear accumulation of PKM2, shifts metabolism toward aerobic glycolysis (increased glucose uptake, lactate release, Glut1 and LDHA mRNA expression). A peptide blocking the SASH1-PKM2 interaction reduces astrocytic activation and promotes wound healing in a mouse TBI model.","method":"Co-immunoprecipitation (SASH1-PKM2), nuclear fractionation, metabolic assays (glucose uptake, lactate release), qPCR, siRNA knockdown, peptide design, mouse TBI model","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing SASH1-PKM2 interaction, metabolic functional assays, peptide disruption in vivo, single lab","pmids":["41690666"],"is_preprint":false},{"year":2016,"finding":"SASH1 inhibits TGF-β1-mediated EMT, cell migration, and invasion in gastric cancer cells, and inhibits phosphorylation of PI3K and Akt in TGF-β1-stimulated cells, placing SASH1 as a negative regulator of the PI3K/Akt pathway downstream of TGF-β1.","method":"SASH1 overexpression, Western blot (PI3K/Akt phosphorylation), migration/invasion assays, EMT marker assays","journal":"Oncology research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single overexpression approach, pathway placement by Western blot only","pmids":["27178818"],"is_preprint":false},{"year":2016,"finding":"SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing FAK expression and signaling, as shown by reduced FAK protein levels upon SASH1 overexpression.","method":"SASH1 overexpression, Western blot (FAK, MMP-2, MMP-9), MTT assay, Transwell assay","journal":"Molecular medicine reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single overexpression approach, pathway placement by Western blot only without direct binding assay","pmids":["26935246"],"is_preprint":false},{"year":2022,"finding":"SASH1 functions as an astrocytic differentiation-maintaining protein. SASH1 knockdown in spinal astrocytes decreases interferon-γ release, increases BDNF release, and reduces GFAP expression. SASH1 expression increases as NSCs differentiate into glial cells; SASH1 depletion maintains higher Nestin levels and increased BDNF in differentiated NSCs. Co-culture of SASH1-knockdown astrocytes with neurons increases axonal growth and TrkB expression in axonal tips.","method":"siRNA knockdown in rat astrocytes, ELISA (IFN-γ, BDNF), Western blot (GFAP, Nestin, TrkB), co-culture axonal growth assay, SCI rat model (in vivo siRNA injection, BBB score)","journal":"CNS neuroscience & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with defined phenotypic readout plus multiple in vitro mechanistic assays, single lab","pmids":["36286186"],"is_preprint":false},{"year":2023,"finding":"SASH1 is required for glial cell migration during embryonic brain development. sash1a morpholino knockdown in zebrafish reduces microglial number in the developing brain and causes abnormal arrangement and disordered orientation of gfap+ glia without affecting motor neuron axonal growth. These phenotypes were rescued by injection of human SASH1 mRNA, confirming functional conservation.","method":"Morpholino oligonucleotide knockdown in zebrafish, CRISPR/Cas9 mutagenesis, transgenic zebrafish lines (Tg(gfap:eGFP), Tg(hb9:eGFP), Tg(coro1a:eGFP)), human SASH1 mRNA rescue, behavioral assays","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino and CRISPR knockdown with specific glial phenotype, human mRNA rescue confirming conservation, single lab","pmids":["37741309"],"is_preprint":false}],"current_model":"SASH1 is a multifunctional scaffold/adaptor protein containing SH3 and SAM domains that assembles signaling complexes at multiple nodes: it binds TRAF6, TAK1, IKKα/β, and β-arrestin 1 downstream of TLR4 to drive NF-κB/JNK/p38 activation and eNOS-mediated nitric oxide production; interacts with CRKL to inhibit SRC kinase and EMT; is cleaved by caspase-3 during apoptosis, allowing its C-terminal fragment to translocate to the nucleus and activate NF-κB-dependent apoptosis; modulates Hippo signaling through LATS1-dependent phosphorylation at S407 and regulation of YAP/ARHGAP42/actin; interacts with cortactin to regulate actin cytoskeleton and cell-matrix adhesion; suppresses PI3K/Akt, Shh-Gli1, FAK, and TGF-β1/THBS1 pathways; binds Eph receptor SAM domains (notably EphA8) to regulate kinase activity; interacts with TNKS2 to maintain melanocyte stem cells; sequesters PKM2 in astrocytes to regulate glycolysis; and is epigenetically silenced by HMGB1/SET/HAT1-mediated histone deacetylation or direct CpG methylation in cancer."},"narrative":{"mechanistic_narrative":"SASH1 is a multidomain SH3/SAM-containing scaffold/adaptor protein that nucleates signaling complexes at the actin cytoskeleton, cell-cell junctions, and inflammatory and growth-control pathways, broadly acting as a tumor-suppressive organizer of adhesion and migration [PMID:21820526, PMID:23776175, PMID:30480076]. In epithelial cells it co-distributes with the actin cytoskeleton and binds cortactin to promote filamentous actin and cell-matrix adhesion while restraining migration, and it localizes to adherens junctions where its loss precipitates a mesenchymal transition [PMID:21820526, PMID:32586229]. As a TLR4 scaffold in endothelial cells, SASH1 independently binds TRAF6, TAK1, and IKKα/β, promotes TRAF6/TAK1 ubiquitination, and drives NF-κB/JNK/p38-dependent inflammatory signaling; downstream it engages β-arrestin 1 to activate Akt and eNOS, and Sash1-null mice die perinatally from defective nitric-oxide-dependent alveolar epithelial maturation [PMID:23776175, PMID:31067462]. SASH1 suppresses tumor cell invasion through several convergent routes: it binds the oncoprotein CRKL to inhibit SRC kinase and block EMT and metastasis [PMID:30480076], and it operates within the Hippo pathway as a LATS1/LATS2 substrate (phosphorylated at S407) that restrains YAP and the downstream YAP-ARHGAP42-actin invasion axis [PMID:32523092, PMID:38657867]. During UVC-induced apoptosis SASH1 is cleaved by caspase-3, and its C-terminal fragment translocates to the nucleus and chromatin to drive NF-κB-dependent apoptosis [PMID:27831555]. Through its SAM1 domain SASH1 engages additional partners—Eph receptors (notably EphA8, by a structurally defined SAM-SAM interaction that modulates kinase activity), Caskin1/2 (disrupting their SAM homopolymer), and tankyrase-2 (TNKS2, required for melanocyte stem-cell maintenance)—establishing the SAM domain as a key interaction hub [PMID:36341956, PMID:37619706, PMID:39688081, PMID:38848986]. SASH1 mutations cause dyschromatosis/dyschromatosis universalis hereditaria with pathological hyperpigmentation through altered melanocyte migration and pigmentation signaling [PMID:23333244, PMID:32174800]. In cancer, SASH1 is epigenetically silenced via HMGB1-directed CpG methylation and an HMGB1/SET/HAT1 histone-deacetylation complex at the SASH1 locus [PMID:31138780, PMID:37794134].","teleology":[{"year":2003,"claim":"Established SASH1 as a candidate signaling adaptor by identifying its SH3 and SAM domains, framing all subsequent mechanistic work as scaffold biology.","evidence":"In silico domain analysis with EST/genomic comparison and Northern blot","pmids":["12771949"],"confidence":"Low","gaps":["Domain inference only, no functional partner or activity demonstrated","No subcellular localization established"]},{"year":2011,"claim":"Connected SASH1 to the actin cytoskeleton, answering what cellular structure it acts on by showing cortactin binding and control of actin-driven adhesion and migration.","evidence":"Immunofluorescence co-localization, domain mapping, F-actin staining, adhesion/migration assays with siRNA in epithelial cells","pmids":["21820526"],"confidence":"Medium","gaps":["Cortactin interaction not validated reciprocally or structurally","Molecular basis of adhesion increase unresolved"]},{"year":2013,"claim":"Defined SASH1 as a TLR4 inflammatory scaffold, resolving how it links receptor engagement to NF-κB/MAPK output via direct binding to multiple pathway kinases.","evidence":"Reciprocal Co-IP of TRAF6/TAK1/IKKα/β, ubiquitination assays, and pathway/cytokine readouts in LPS-stimulated endothelial cells","pmids":["23776175"],"confidence":"High","gaps":["Stoichiometry and order of complex assembly not defined","Which domain mediates each kinase contact unknown"]},{"year":2013,"claim":"Linked SASH1 mutations to a disease mechanism by showing mutant SASH1 increases melanocyte migration through altered IQGAP1/Gαs binding and E-cadherin loss.","evidence":"Patient mutation analysis, Co-IP (IQGAP1, Gαs), migration assays, E-cadherin Western blot","pmids":["23333244"],"confidence":"Medium","gaps":["Direct vs indirect binding of IQGAP1/Gαs unresolved","How mutation alters binding mechanistically not shown"]},{"year":2016,"claim":"Revealed a caspase-regulated nuclear function, showing caspase-3 cleavage generates a C-terminal fragment that drives NF-κB-dependent apoptosis.","evidence":"Caspase cleavage assays, cleavage-site mutagenesis, subcellular fractionation, NF-κB inhibitor (DHMEQ) after UVC","pmids":["27831555"],"confidence":"High","gaps":["Nuclear targets of the cleaved fragment not identified","Mechanism of NF-κB activation by the fragment undefined"]},{"year":2016,"claim":"Placed SASH1 upstream of multiple oncogenic kinase/morphogen pathways (Shh-Gli1, PI3K/Akt, FAK) as a suppressor of proliferation and invasion.","evidence":"Overexpression with pharmacological agonist rescue, Western blot pathway readouts, xenograft and Transwell assays across hepatocarcinoma, gastric and cervical cancer models","pmids":["28600143","27178818","26935246"],"confidence":"Medium","gaps":["Pathway placements rely on Western blot/epistasis without direct binding for several","Direct molecular target within each pathway unidentified"]},{"year":2017,"claim":"Showed SASH1 governs epithelial lumenogenesis through a DLK1-NOTCH1 axis downstream of CEACAM1.","evidence":"RNAi, 3D lumen formation assay, gene array, DLK1 RNAi and γ-secretase epistasis","pmids":["28823832"],"confidence":"Medium","gaps":["How SASH1 controls DLK1 expression unknown","No physical interaction defined in this axis"]},{"year":2018,"claim":"Identified CRKL as a direct partner whose SRC activation SASH1 inhibits, providing a defined molecular route by which SASH1 suppresses EMT and metastasis.","evidence":"Y2H, Co-IP/MS, domain mapping, dynamic mass redistribution, CRISPR knockout and in vivo metastasis with CRKL-dependent epistasis","pmids":["30480076"],"confidence":"High","gaps":["How CRKL binding restrains SRC mechanistically not fully resolved","Structural basis of SASH1-CRKL contact undefined"]},{"year":2019,"claim":"Defined an essential developmental role: endothelial SASH1 acts through β-arrestin 1 to drive eNOS/NO signaling that non-autonomously matures alveolar epithelium.","evidence":"Global and endothelial-conditional Sash1 knockout mice, Co-IP (β-arrestin 1), eNOS/Akt/cGMP assays, surfactant and histology","pmids":["31067462"],"confidence":"High","gaps":["Relationship between β-arrestin1 and TLR4 kinase complex unresolved","Direct vs indirect eNOS activation mechanism not detailed"]},{"year":2019,"claim":"Established epigenetic silencing of SASH1 via HMGB1-directed CpG methylation, with downstream integrin β8 control of adhesion/migration.","evidence":"Methylation assay, ChIP (HMGB1 at SASH1 CpG islands), HMGB1 overexpression, integrin β8 Western blot in astrocytes","pmids":["31138780"],"confidence":"Medium","gaps":["Methyltransferase recruited by HMGB1 not identified","Direct vs indirect integrin β8 regulation unclear"]},{"year":2020,"claim":"Embedded SASH1 in Hippo signaling as both a LATS substrate (S407) and regulator of YAP, defining the YAP-ARHGAP42-actin axis driving invasion.","evidence":"Phospho-Western, S407A mutagenesis with rescue failure, YAP/ARHGAP42 epistasis, CAM and xenograft models in TNBC","pmids":["32523092"],"confidence":"High","gaps":["How SASH1 reciprocally promotes LATS1 activity unknown","Functional consequence of S407 phosphorylation on SASH1 structure undefined"]},{"year":2020,"claim":"Reinforced SASH1's adhesion-maintaining role and characterized melanocyte-pigmentation mechanisms (Mitf, THBS1/TGF-β1) underlying its mutation phenotypes.","evidence":"Confocal localization at adherens junctions with RNAi (epithelial cells); Y551D knock-in mice with Mitf IHC; patient-mutation THBS1/TGF-β1 migration assays","pmids":["32586229","32582980","32174800"],"confidence":"Medium","gaps":["Whether SASH1 directly binds Mitf complex unproven","Mechanism linking SASH1 to THBS1 transcription unresolved"]},{"year":2022,"claim":"Provided the first structural insight into the SAM1 domain, showing it is a predominantly disordered monomer distinct from related SAM domains, with a mapped oligomerization region.","evidence":"NMR, SEC-MALS, SE-HPLC and D663A/T664K mutagenesis","pmids":["36341956"],"confidence":"High","gaps":["Functional role of monomeric vs oligomeric state in cells unknown","Link between oligomerization and partner binding untested"]},{"year":2022,"claim":"Extended SASH1's TRAF6-ubiquitination scaffold function to stabilize EZH2 and identified roles in glial differentiation maintenance.","evidence":"Co-IP/ubiquitination assays with EZH2 rescue in hemangioma endothelial cells; siRNA in astrocytes with ELISA/Western and co-culture axonal assays","pmids":["35772492","36286186"],"confidence":"Medium","gaps":["How SASH1 promotes TRAF6 ubiquitination toward EZH2 stability unclear","Direct vs indirect control of glial differentiation factors undefined"]},{"year":2023,"claim":"Established the SAM1 domain as a versatile interaction hub by defining structurally resolved interactions with Eph receptors (EphA8) and Caskin1/2.","evidence":"Crystal structure of EphA8-SASH1, Co-IP, kinase assays, cancer mutation analysis; Y2H/ITC/GST pulldown with AlphaFold2 modeling and polymer-disruption assays for Caskin","pmids":["37619706","39688081"],"confidence":"High","gaps":["Cellular consequence of SASH1 on EphA8 signaling output beyond kinase assay limited","Physiological context of SASH1-Caskin interaction not established"]},{"year":2023,"claim":"Identified TNKS2 as a SASH1 partner required for melanocyte stem-cell maintenance, with a disease variant (S519N) in the tankyrase-binding motif impairing this function.","evidence":"Y2H, binding kinetics/affinity assays, stem-cell functional assays (preprint then peer-reviewed) with S519N variant analysis","pmids":["37808724","38848986"],"confidence":"Medium","gaps":["Downstream consequence of TNKS2 binding on SASH1 fate unknown","Whether SASH1 is a tankyrase substrate untested"]},{"year":2023,"claim":"Demonstrated functional conservation of SASH1 in glial migration during brain development using zebrafish with human mRNA rescue.","evidence":"sash1a morpholino/CRISPR knockdown, transgenic reporter lines, human SASH1 mRNA rescue","pmids":["37741309"],"confidence":"Medium","gaps":["Molecular pathway driving glial migration phenotype unidentified","Cell-autonomous vs non-autonomous requirement unresolved"]},{"year":2024,"claim":"Extended the Hippo connection by identifying a MAP4K4-LATS2-SASH1-YAP1 cascade, with LATS2 directly phosphorylating SASH1.","evidence":"LATS2 kinase assay on SASH1, overexpression/siRNA epistasis, nuclear fractionation, tumor models in luminal breast cancer","pmids":["38657867"],"confidence":"Medium","gaps":["Phosphosite(s) targeted by LATS2 not mapped","How SASH1 transmits to YAP1 within the cascade unclear"]},{"year":2026,"claim":"Revealed a metabolic role in which SASH1 sequesters PKM2 in astrocytes to restrain glycolysis, with a disrupting peptide promoting TBI wound healing.","evidence":"Co-IP (SASH1-PKM2), nuclear fractionation, metabolic assays, peptide disruption in a mouse TBI model","pmids":["41690666"],"confidence":"Medium","gaps":["Structural basis of SASH1-PKM2 interaction undefined","Whether this mechanism operates in other cell types unknown"]},{"year":null,"claim":"How SASH1's many partner interactions are coordinated by its SH3 and SAM domains into context-specific complexes, and which domain configurations switch it between adhesion, inflammatory, Hippo, and metabolic functions, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated structural model of full-length SASH1 with multiple partners","Determinants of cell-type-specific partner selection unknown","Post-translational regulation governing function-switching incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,8,17,19]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[1,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,8,11,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,4,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,4]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[1,12]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,8,11,17,20]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,28]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[1,12]}],"complexes":["TLR4-TRAF6-TAK1-IKK scaffold complex"],"partners":["TRAF6","CRKL","ARRB1","LATS1","EPHA8","CASKIN1","TNKS2","PKM2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O94885","full_name":"SAM and SH3 domain-containing protein 1","aliases":["Proline-glutamate repeat-containing protein"],"length_aa":1247,"mass_kda":136.7,"function":"Is a positive regulator of NF-kappa-B signaling downstream of TLR4 activation. It acts as a scaffold molecule to assemble a molecular complex that includes TRAF6, MAP3K7, CHUK and IKBKB, thereby facilitating NF-kappa-B signaling activation (PubMed:23776175). Regulates TRAF6 and MAP3K7 ubiquitination (PubMed:23776175). Involved in the regulation of cell mobility (PubMed:23333244, PubMed:23776175, PubMed:25315659). Regulates lipolysaccharide (LPS)-induced endothelial cell migration (PubMed:23776175). Is involved in the regulation of skin pigmentation through the control of melanocyte migration in the epidermis (PubMed:23333244)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O94885/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SASH1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SASH1","total_profiled":1310},"omim":[{"mim_id":"618373","title":"CANCER, ALOPECIA, PIGMENT DYSCRASIA, ONYCHODYSTROPHY, AND KERATODERMA; CAPOK","url":"https://www.omim.org/entry/618373"},{"mim_id":"607955","title":"SAM- AND SH3 DOMAIN-CONTAINING PROTEIN 1; SASH1","url":"https://www.omim.org/entry/607955"},{"mim_id":"602355","title":"TNF RECEPTOR-ASSOCIATED FACTOR 6; TRAF6","url":"https://www.omim.org/entry/602355"},{"mim_id":"176876","title":"PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 11; PTPN11","url":"https://www.omim.org/entry/176876"},{"mim_id":"148000","title":"KAPOSI SARCOMA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/148000"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SASH1"},"hgnc":{"alias_symbol":["KIAA0790","dJ323M4.1","SH3D6A"],"prev_symbol":[]},"alphafold":{"accession":"O94885","domains":[{"cath_id":"2.30.30.40","chopping":"558-614","consensus_level":"high","plddt":92.9923,"start":558,"end":614},{"cath_id":"1.10.150.50","chopping":"639-696","consensus_level":"high","plddt":91.1881,"start":639,"end":696},{"cath_id":"-","chopping":"1106-1174","consensus_level":"medium","plddt":86.1591,"start":1106,"end":1174},{"cath_id":"1.10.150.50","chopping":"1178-1242","consensus_level":"medium","plddt":86.0872,"start":1178,"end":1242}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O94885","model_url":"https://alphafold.ebi.ac.uk/files/AF-O94885-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O94885-F1-predicted_aligned_error_v6.png","plddt_mean":54.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SASH1","jax_strain_url":"https://www.jax.org/strain/search?query=SASH1"},"sequence":{"accession":"O94885","fasta_url":"https://rest.uniprot.org/uniprotkb/O94885.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O94885/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O94885"}},"corpus_meta":[{"pmid":"12771949","id":"PMC_12771949","title":"SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12771949","citation_count":122,"is_preprint":false},{"pmid":"15279899","id":"PMC_15279899","title":"C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15279899","citation_count":110,"is_preprint":false},{"pmid":"21820526","id":"PMC_21820526","title":"The candidate tumor suppressor SASH1 interacts with the actin cytoskeleton and stimulates cell-matrix adhesion.","date":"2011","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21820526","citation_count":51,"is_preprint":false},{"pmid":"23776175","id":"PMC_23776175","title":"SASH1 is a scaffold molecule in endothelial TLR4 signaling.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23776175","citation_count":50,"is_preprint":false},{"pmid":"23108792","id":"PMC_23108792","title":"SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell.","date":"2012","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23108792","citation_count":44,"is_preprint":false},{"pmid":"23333244","id":"PMC_23333244","title":"SASH1 regulates melanocyte transepithelial migration through a novel Gαs-SASH1-IQGAP1-E-Cadherin dependent pathway.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23333244","citation_count":44,"is_preprint":false},{"pmid":"25315659","id":"PMC_25315659","title":"Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma.","date":"2014","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/25315659","citation_count":43,"is_preprint":false},{"pmid":"30480076","id":"PMC_30480076","title":"The Tumor Suppressor SASH1 Interacts With the Signal Adaptor CRKL to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.","date":"2018","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30480076","citation_count":40,"is_preprint":false},{"pmid":"27178818","id":"PMC_27178818","title":"Overexpression of SASH1 Inhibits TGF-β1-Induced EMT in Gastric Cancer Cells.","date":"2016","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/27178818","citation_count":37,"is_preprint":false},{"pmid":"22488244","id":"PMC_22488244","title":"Effects of SASH1 on lung cancer cell proliferation, apoptosis, and invasion in vitro.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22488244","citation_count":36,"is_preprint":false},{"pmid":"16137664","id":"PMC_16137664","title":"Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells.","date":"2005","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16137664","citation_count":36,"is_preprint":false},{"pmid":"22915266","id":"PMC_22915266","title":"Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22915266","citation_count":31,"is_preprint":false},{"pmid":"28600143","id":"PMC_28600143","title":"Involvement of PI3K/Akt pathway in the inhibition of hepatocarcinoma cell invasion and metastasis induced by SASH1 through downregulating Shh-Gli1 signaling.","date":"2017","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28600143","citation_count":30,"is_preprint":false},{"pmid":"23023727","id":"PMC_23023727","title":"Effects of SASH1 on melanoma cell proliferation and apoptosis in vitro.","date":"2012","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/23023727","citation_count":28,"is_preprint":false},{"pmid":"26318107","id":"PMC_26318107","title":"SASH1, a new potential link between smoking and atherosclerosis.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26318107","citation_count":27,"is_preprint":false},{"pmid":"27178819","id":"PMC_27178819","title":"Overexpression of SASH1 Inhibits the Proliferation, Invasion, and EMT in Hepatocarcinoma Cells.","date":"2016","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/27178819","citation_count":27,"is_preprint":false},{"pmid":"32523092","id":"PMC_32523092","title":"SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32523092","citation_count":25,"is_preprint":false},{"pmid":"27831555","id":"PMC_27831555","title":"Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27831555","citation_count":25,"is_preprint":false},{"pmid":"27885802","id":"PMC_27885802","title":"A novel P53/POMC/Gαs/SASH1 autoregulatory feedback loop activates mutated SASH1 to cause pathologic hyperpigmentation.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27885802","citation_count":24,"is_preprint":false},{"pmid":"26722413","id":"PMC_26722413","title":"SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722413","citation_count":22,"is_preprint":false},{"pmid":"33571015","id":"PMC_33571015","title":"CircRNA Circ-ITCH Inhibits the Proliferation and Invasion of Glioma Cells Through Targeting the miR-106a-5p/SASH1 Axis.","date":"2021","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/33571015","citation_count":22,"is_preprint":false},{"pmid":"33710696","id":"PMC_33710696","title":"The emerging and diverse roles of the SLy/SASH1-protein family in health and disease-Overview of three multifunctional proteins.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33710696","citation_count":21,"is_preprint":false},{"pmid":"27659786","id":"PMC_27659786","title":"Lentiginous phenotypes caused by diverse pathogenic genes (SASH1 and PTPN11): clinical and molecular discrimination.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27659786","citation_count":21,"is_preprint":false},{"pmid":"31067462","id":"PMC_31067462","title":"Endothelial Sash1 Is Required for Lung Maturation through Nitric Oxide Signaling.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31067462","citation_count":20,"is_preprint":false},{"pmid":"32174800","id":"PMC_32174800","title":"SASH1 promotes melanin synthesis and migration via suppression of TGF-β1 secretion in melanocytes resulting in pathologic hyperpigmentation.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32174800","citation_count":20,"is_preprint":false},{"pmid":"31138780","id":"PMC_31138780","title":"HMGB1 contributes to SASH1 methylation to attenuate astrocyte adhesion.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31138780","citation_count":19,"is_preprint":false},{"pmid":"26935246","id":"PMC_26935246","title":"SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing the FAK pathway.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26935246","citation_count":19,"is_preprint":false},{"pmid":"31421824","id":"PMC_31421824","title":"Exosomal and extracellular HMGB1 have opposite effects on SASH1 expression in rat astrocytes and glioma C6 cells.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31421824","citation_count":18,"is_preprint":false},{"pmid":"30396754","id":"PMC_30396754","title":"MicroRNA-17 promotes osteosarcoma cells proliferation and migration and inhibits apoptosis by regulating SASH1 expression.","date":"2018","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/30396754","citation_count":18,"is_preprint":false},{"pmid":"26424902","id":"PMC_26424902","title":"Clinical Significance of SASH1 Expression in Glioma.","date":"2015","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/26424902","citation_count":17,"is_preprint":false},{"pmid":"30443973","id":"PMC_30443973","title":"MiR-130b promotes the progression of oesophageal squamous cell carcinoma by targeting SASH1.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30443973","citation_count":16,"is_preprint":false},{"pmid":"34174894","id":"PMC_34174894","title":"Novel missense mutation of SASH1 in a Chinese family with dyschromatosis universalis hereditaria.","date":"2021","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34174894","citation_count":15,"is_preprint":false},{"pmid":"32981204","id":"PMC_32981204","title":"Five novel mutations in SASH1 contribute to lentiginous phenotypes in Japanese families.","date":"2020","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/32981204","citation_count":14,"is_preprint":false},{"pmid":"32849825","id":"PMC_32849825","title":"Identification of a Novel Mutation in SASH1 Gene in a Chinese Family With Dyschromatosis Universalis Hereditaria and Genotype-Phenotype Correlation Analysis.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32849825","citation_count":14,"is_preprint":false},{"pmid":"36286186","id":"PMC_36286186","title":"Depletion of SASH1, an astrocyte differentiation-related gene, contributes to functional recovery in spinal cord injury.","date":"2022","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36286186","citation_count":12,"is_preprint":false},{"pmid":"25536614","id":"PMC_25536614","title":"Promoter methylation assay of SASH1 gene in hepatocellular carcinoma.","date":"2014","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25536614","citation_count":12,"is_preprint":false},{"pmid":"34028087","id":"PMC_34028087","title":"Two novel SASH1 mutations in Chinese families with dyschromatosis universalis hereditaria.","date":"2021","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/34028087","citation_count":12,"is_preprint":false},{"pmid":"33134379","id":"PMC_33134379","title":"Expression of SASH1 in Preeclampsia and Its Effects on Human Trophoblast.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/33134379","citation_count":11,"is_preprint":false},{"pmid":"24344014","id":"PMC_24344014","title":"Promoter methylation assay of SASH1 gene in breast cancer.","date":"2013","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24344014","citation_count":11,"is_preprint":false},{"pmid":"32547092","id":"PMC_32547092","title":"SASH1 Suppresses the Proliferation and Invasion of Human Skin Squamous Cell Carcinoma Cells via Inhibiting Akt Cascade.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32547092","citation_count":11,"is_preprint":false},{"pmid":"32586229","id":"PMC_32586229","title":"Involvement of SASH1 in the Maintenance of Stable Cell-Cell Adhesion.","date":"2020","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/32586229","citation_count":10,"is_preprint":false},{"pmid":"37794134","id":"PMC_37794134","title":"HMGB1/SET/HAT1 complex-mediated SASH1 repression drives glycolysis and metastasis in lung adenocarcinoma.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/37794134","citation_count":10,"is_preprint":false},{"pmid":"29805606","id":"PMC_29805606","title":"Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29805606","citation_count":10,"is_preprint":false},{"pmid":"32582980","id":"PMC_32582980","title":"Mutated SASH1 promotes Mitf expression in a heterozygous mutated SASH1 knock‑in mouse model.","date":"2020","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32582980","citation_count":8,"is_preprint":false},{"pmid":"28138250","id":"PMC_28138250","title":"Correlation of SASH1 expression and ultrasonographic features in breast cancer.","date":"2017","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28138250","citation_count":8,"is_preprint":false},{"pmid":"37510314","id":"PMC_37510314","title":"Human Endogenous Retrovirus-H-Derived miR-4454 Inhibits the Expression of DNAJB4 and SASH1 in Non-Muscle-Invasive Bladder Cancer.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37510314","citation_count":8,"is_preprint":false},{"pmid":"36341956","id":"PMC_36341956","title":"SAM1 domain of SASH1 harbors distinctive structural heterogeneity.","date":"2022","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/36341956","citation_count":7,"is_preprint":false},{"pmid":"28823832","id":"PMC_28823832","title":"The adaptor SASH1 acts through NOTCH1 and its inhibitor DLK1 in a 3D model of lumenogenesis involving CEACAM1.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28823832","citation_count":7,"is_preprint":false},{"pmid":"37619706","id":"PMC_37619706","title":"SASH1: A Novel Eph Receptor Partner and Insights into SAM-SAM Interactions.","date":"2023","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37619706","citation_count":6,"is_preprint":false},{"pmid":"35772492","id":"PMC_35772492","title":"SASH1 knockdown suppresses TRAF6 ubiquitination to regulate hemangioma progression by mediating EZH2 degradation.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35772492","citation_count":5,"is_preprint":false},{"pmid":"38657867","id":"PMC_38657867","title":"Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38657867","citation_count":5,"is_preprint":false},{"pmid":"37741309","id":"PMC_37741309","title":"SASH1 contributes to glial cell migration in the early development of the central nervous system.","date":"2023","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37741309","citation_count":5,"is_preprint":false},{"pmid":"37543808","id":"PMC_37543808","title":"Uncovering a new SASH1 mutation associated with dyschromatosis universalis hereditaria using whole-exome-sequencing: A case report.","date":"2023","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37543808","citation_count":5,"is_preprint":false},{"pmid":"39300116","id":"PMC_39300116","title":"The downregulation of SASH1 expression promotes breast cancer occurrence and invasion accompanied by the activation of PI3K-Akt-mTOR signaling pathway.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39300116","citation_count":4,"is_preprint":false},{"pmid":"40511878","id":"PMC_40511878","title":"SASH1 Mutations and Hereditary Disorders of Pigmentation: Review of Literature.","date":"2025","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/40511878","citation_count":3,"is_preprint":false},{"pmid":"33297837","id":"PMC_33297837","title":"AAV1-Mediated shRNA Knockdown of SASH1 in Rat Bronchus Attenuates Hypoxia-Induced Pulmonary Artery Remodeling.","date":"2021","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33297837","citation_count":3,"is_preprint":false},{"pmid":"37155029","id":"PMC_37155029","title":"Solution NMR backbone assignment of the SASH1 SLy proteins associated disordered region (SPIDER).","date":"2023","source":"Biomolecular NMR assignments","url":"https://pubmed.ncbi.nlm.nih.gov/37155029","citation_count":3,"is_preprint":false},{"pmid":"38848986","id":"PMC_38848986","title":"SASH1 S519N Variant Links Skin Hyperpigmentation and Premature Hair Graying to Dysfunction of Melanocyte Lineage.","date":"2024","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/38848986","citation_count":3,"is_preprint":false},{"pmid":"37808724","id":"PMC_37808724","title":"SASH1 interacts with TNKS2 and promotes human melanocyte stem cell maintenance.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37808724","citation_count":2,"is_preprint":false},{"pmid":"39664191","id":"PMC_39664191","title":"Gastric cancer cell-derived exosomal miRNA-128-3p promotes angiogenesis by targeting SASH1.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39664191","citation_count":1,"is_preprint":false},{"pmid":"39688081","id":"PMC_39688081","title":"SASH1 is a novel binding partner to disassemble Caskin1 tandem SAM homopolymer through heterogeneous SAM-SAM interaction.","date":"2024","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/39688081","citation_count":1,"is_preprint":false},{"pmid":"40584949","id":"PMC_40584949","title":"Dyschromatosis universalis hereditaria with SASH1 mutation improved with picosecond laser treatment.","date":"2025","source":"Skin health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/40584949","citation_count":0,"is_preprint":false},{"pmid":"41284354","id":"PMC_41284354","title":"SASH1 Modulates Melanin Synthesis and Melanoma Cell Metastasis via Suppression of the TGF-β Signaling Pathway.","date":"2025","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/41284354","citation_count":0,"is_preprint":false},{"pmid":"39942820","id":"PMC_39942820","title":"Sam-Sam Association Between EphA2 and SASH1: In Silico Studies of Cancer-Linked Mutations.","date":"2025","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/39942820","citation_count":0,"is_preprint":false},{"pmid":"41899638","id":"PMC_41899638","title":"Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib.","date":"2026","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/41899638","citation_count":0,"is_preprint":false},{"pmid":"41690666","id":"PMC_41690666","title":"A peptide drug targeting SASH1-PKM2 interaction promotes recovery of traumatic brain injury in mice.","date":"2026","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/41690666","citation_count":0,"is_preprint":false},{"pmid":"40115815","id":"PMC_40115815","title":"Case report: Clinicopathological characteristics of SASH1 mutation-related dyschromatosis: a rethinking of the classification of dyschromatosis.","date":"2025","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40115815","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35297,"output_tokens":8323,"usd":0.115368,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17841,"output_tokens":6050,"usd":0.120228,"stage2_stop_reason":"end_turn"},"total_usd":0.235596,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"SASH1 encodes a member of the SH3/SAM adapter molecule family, with protein domain analysis revealing SH3 and SAM domains, suggesting a role in signaling pathways. Two transcripts (~4.4 and ~7.5 kb) were identified.\",\n      \"method\": \"In silico domain analysis, EST/genomic sequence comparison, Northern blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — domain-based inference only, no direct functional experiment on protein mechanism\",\n      \"pmids\": [\"12771949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SASH1 localizes to the nucleus, cytoplasm, lamellipodia, and membrane ruffles in epithelial cells, where it co-distributes with the actin cytoskeleton. SASH1 interacts with cortactin (an actin polymerization regulator). Overexpression increases filamentous actin content and cell protrusions; this activity maps to the central conserved domain. SASH1 overexpression inhibits cell migration and increases adhesion to fibronectin and laminin, while knockdown reduces cell-matrix adhesion.\",\n      \"method\": \"Immunofluorescence/co-localization, structural domain mutants, F-actin staining, migration assays, adhesion assays, siRNA knockdown\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple orthogonal methods (localization, co-distribution, domain mapping, functional assays), single lab\",\n      \"pmids\": [\"21820526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SASH1 acts as a scaffold protein in TLR4 signaling in endothelial cells, independently binding TRAF6, TAK1, IκB kinase α, and IκB kinase β. This interaction fosters ubiquitination of TRAF6 and TAK1 and promotes LPS-induced NF-κB, JNK, and p38 activation, increasing proinflammatory cytokine production and LPS-induced endothelial migration.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, LPS stimulation, NF-κB/JNK/p38 pathway assays, cytokine measurements, migration assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying multiple binding partners, ubiquitination assays, multiple downstream pathway readouts, functional phenotype\",\n      \"pmids\": [\"23776175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SASH1 mutations associated with dyschromatosis cause increased melanocyte migration. Mutated SASH1 shows intensified binding with IQGAP1 and Gαs, and induces uniform loss of E-Cadherin in A375 cells, suggesting SASH1 regulates IQGAP1-E-Cadherin signaling and acts as a scaffold linking GPCR/calmodulin signaling to melanocyte invasion.\",\n      \"method\": \"Patient mutation identification, functional cell migration assays, co-immunoprecipitation (IQGAP1, Gαs binding), Western blot (E-Cadherin)\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP of binding partners, functional migration assay, single lab with multiple methods\",\n      \"pmids\": [\"23333244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SASH1 is cleaved by caspase-3 following UVC-induced apoptosis. The C-terminal cleavage fragment (aa 231–1247) translocates from the cytoplasm to the nucleus and associates with chromatin. Overexpression of wild-type or cleaved SASH1 increases apoptosis; mutation of the cleavage site inhibits nuclear translocation and prevents apoptosis initiation. SASH1 cleavage is required for efficient nuclear translocation of NF-κB, and the effect of SASH1 on apoptosis is NF-κB-dependent (demonstrated by DHMEQ inhibitor).\",\n      \"method\": \"Caspase cleavage assays, UVC treatment, subcellular fractionation/immunofluorescence (nuclear translocation), site-directed mutagenesis of cleavage site, apoptosis assays, NF-κB inhibitor (DHMEQ)\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro cleavage assay, mutagenesis of cleavage site with functional consequence, subcellular localization, pharmacological inhibitor validation, multiple orthogonal methods\",\n      \"pmids\": [\"27831555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SASH1 is regulated by a p53/POMC/α-MSH/Gαs/SASH1 cascade mediating melanogenesis. A novel p53/POMC/Gαs/SASH1 autoregulatory positive feedback loop is activated by SASH1 mutations to induce pathological hyperpigmentation. SASH1 is physiologically induced by p53 upon UV stimulation, and SASH1 and p53 are reciprocally induced.\",\n      \"method\": \"Reporter assays, Western blot, UV stimulation experiments, patient mutation analysis, pathway activation assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pathway activation experiments with multiple components, single lab, mechanistic follow-up limited to abstract description\",\n      \"pmids\": [\"27885802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SASH1 overexpression suppresses Shh and downstream Gli1, Smo, Ptc signaling in hepatocarcinoma cells, inhibiting proliferation and invasion. This effect was reversed by Shh pathway agonist purmorphamine or PI3K/Akt agonists (740Y-P, PDGF), placing SASH1 upstream of Shh-Gli1 and PI3K/Akt pathways to inhibit invasion and metastasis in vivo and in vitro.\",\n      \"method\": \"Western blot, qRT-PCR, Transwell assay, pharmacological agonist rescue (purmorphamine, 740Y-P, PDGF), orthotopic xenograft mouse model\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via pharmacological rescue in vitro and in vivo, multiple pathway readouts, single lab\",\n      \"pmids\": [\"28600143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SASH1 is critical for lumen formation in a 3D breast cancer model. SASH1 RNAi inhibits lumen formation downstream of CEACAM1. SASH1 acts through DLK1 (a NOTCH1 inhibitor) to regulate NOTCH1 signaling; SASH1 RNAi down-regulates DLK1, and DLK1 RNAi also inhibits lumen formation. NOTCH1 and its target genes HES1 and HEY1 are up-regulated by SASH1 RNAi and down-regulated by DLK1 RNAi, placing SASH1 upstream of DLK1-NOTCH1 in lumenogenesis.\",\n      \"method\": \"RNAi knockdown, 3D culture lumen formation assay, gene array, epistasis (DLK1 RNAi, γ-secretase inhibitor)\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via RNAi and pharmacological inhibition, functional 3D assay, single lab\",\n      \"pmids\": [\"28823832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SASH1 interacts with the oncoprotein CRKL (identified by yeast 2-hybrid and co-immunoprecipitation/mass spectrometry, confirmed by domain mapping, site-directed mutagenesis, and dynamic mass redistribution assays). SASH1 inhibits CRKL-mediated activation of SRC kinase, which is required for EMT. SASH1-deficient colon cancer cells undergo EMT and form more metastases in vivo; these effects depend entirely on CRKL.\",\n      \"method\": \"Yeast 2-hybrid, co-immunoprecipitation/mass spectrometry, domain mapping, site-directed mutagenesis, dynamic mass redistribution assay, CRISPR/Cas9 knockout, RNAi, EMT assays, orthotopic mouse metastasis model\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Y2H, Co-IP/MS, mutagenesis, dynamic mass redistribution), in vivo epistasis, single lab with rigorous controls\",\n      \"pmids\": [\"30480076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Endothelial Sash1 interacts with β-arrestin 1 downstream of the TLR4 pathway to activate Akt and endothelial nitric oxide synthase (eNOS) in microvascular endothelial cells. Nitric oxide generated downstream of Sash1 in endothelial cells affects alveolar epithelial cells in a cGMP-dependent manner, inducing maturation of alveolar type 1 and 2 cells and promoting pulmonary surfactant production. Sash1-/- mice die perinatally from respiratory distress due to delayed alveolar epithelial maturation.\",\n      \"method\": \"Sash1 knockout mouse generation, endothelial-restricted conditional knockout, co-immunoprecipitation (β-arrestin 1), eNOS/Akt activity assays, cGMP pathway assays, surfactant protein measurement, histology\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic knockout with defined phenotype, Co-IP identifying binding partner, biochemical pathway assays (eNOS, Akt, cGMP), cell-nonautonomous mechanism validated in vivo\",\n      \"pmids\": [\"31067462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HMGB1 contributes to methylation of SASH1 gene CpG islands (demonstrated by ChIP assay showing HMGB1 binding to SASH1 CpG islands); HMGB1 overexpression in astrocytes increases SASH1 methylation level. Reduced SASH1 expression in turn decreases integrin β8 expression, reducing cell adhesion and promoting migration.\",\n      \"method\": \"Methylation assay, ChIP assay (HMGB1 binding to SASH1 CpG islands), HMGB1 overexpression, integrin β8 Western blot, adhesion/invasion assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP identifies HMGB1 as writer of SASH1 methylation, downstream integrin β8 effect shown by Western blot, single lab\",\n      \"pmids\": [\"31138780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SASH1 knockdown in TNBC cells downregulates phosphorylation of LATS1 and its effector YAP, leading to YAP accumulation and upregulation of CYR61. SASH1-induced YAP regulation is LATS1-dependent; in reverse, LATS1 phosphorylates SASH1 at S407. The phosphorylation-deficient SASH1 S407A mutant fails to rescue altered YAP signaling. SASH1 depletion upregulates ARHGAP42 via YAP-TEAD, and the YAP-ARHGAP42-actin axis drives SASH1-regulated TNBC cell invasion.\",\n      \"method\": \"siRNA knockdown, SASH1 overexpression, phospho-Western blot (LATS1, YAP), CYR61 assay, YAP pharmacological inhibitor and siRNA epistasis, S407A mutagenesis, ARHGAP42 knockdown, chicken CAM and mouse xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — phosphorylation site mutagenesis with functional rescue, epistasis via multiple knockdown approaches and pharmacological inhibitor, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"32523092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SASH1 co-localizes with linear adherens junctions (AJs) and circumferential actin bundles in normal epithelial cells. SASH1 depletion by RNAi in IAR-20 cells destroys stable linear AJs and induces acquisition of mesenchymal phenotype, demonstrating SASH1's role in maintaining stable cell-cell adhesion.\",\n      \"method\": \"Immunofluorescence, confocal microscopy, RNAi knockdown, EMT assay\",\n      \"journal\": \"Biochemistry. Biokhimiia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization and loss-of-function with specific structural phenotype (AJ disruption), single lab\",\n      \"pmids\": [\"32586229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mutated SASH1 (Y551D) knock-in mice show increased expression of Mitf (microphthalmia-associated transcription factor) in tail epithelium and increased Mitf-positive epithelial cells, recapitulating DUH hyperpigmentation. SASH1 may function as a scaffold to assemble a SASH1-Mitf molecular complex regulating Mitf expression in the nucleus.\",\n      \"method\": \"Heterozygous SASH1 knock-in mouse model (Y551D), immunohistochemistry, in vitro cell assays\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knock-in model with defined molecular phenotype (Mitf upregulation), corroborated in vitro, single lab\",\n      \"pmids\": [\"32582980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SASH1 mutations (identified in DUH families) downregulate THBS1 (thrombospondin 1) expression and inactivate TGF-β1 signaling, promoting melanocyte migration and invasion. TGF-β1 expressed by melanocytes negatively regulates SASH1 protein expression, establishing a reciprocal regulatory relationship.\",\n      \"method\": \"Patient mutation identification, bioinformatics (THBS1 pathway), Transwell/wound-healing migration assays, Western blot (TGF-β1, SASH1), melanin content measurement\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional cell assays with pathway context, single lab, mechanistic detail limited in abstract\",\n      \"pmids\": [\"32174800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The SAM1 domain of SASH1 exists primarily as a disordered monomer with a minor oligomer in solution, unlike the dimeric SAM domain of the related SASH3. NMR and SEC-MALS characterization revealed multiple timescale exchange regimes. D663A/T664K substitutions in SAM1 increased oligomerization, identifying a region important for oligomerization.\",\n      \"method\": \"SEC-MALS, HPLC, NMR (assignment, relaxation, exchange experiments), site-directed mutagenesis (D663A/T664K), SE-HPLC\",\n      \"journal\": \"Journal of structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biophysical structural characterization with NMR and SEC-MALS, mutagenesis validating oligomerization region, single lab with multiple orthogonal techniques\",\n      \"pmids\": [\"36341956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SASH1 knockdown in hemangioma endothelial cells (HemECs) suppresses TRAF6 ubiquitination, leading to destabilization and reduced expression of EZH2. Co-immunoprecipitation confirmed regulation of TRAF6 and EZH2 ubiquitination by SASH1. EZH2 overexpression reversed the anti-proliferative and pro-apoptotic effects of SASH1 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, CCK-8/cell cycle/apoptosis assays, wound healing/Transwell assays, EZH2 overexpression rescue\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitination assays establish mechanistic link, rescue experiment with EZH2 overexpression, single lab\",\n      \"pmids\": [\"35772492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SASH1 is a novel binding partner of Eph receptors, interacting via SAM-SAM domain interactions. SASH1 selectively interacts with Eph receptors through its SAM1 domain, with highest affinity for EphA8. The crystal structure of the EphA8-SASH1 complex revealed specific intermolecular interactions. EphA8 and SASH1 co-localize and co-precipitate in mammalian cells. Cancer mutations (EphA8 R942H or G978D) impair this interaction. SAM-SAM interaction is critical for SASH1-mediated regulation of EphA8 kinase activity.\",\n      \"method\": \"Crystal structure determination, biochemical binding assays, co-immunoprecipitation, co-localization assays in mammalian cells, cancer mutation analysis, kinase activity assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of complex plus biochemical assays plus cellular co-IP plus functional kinase activity assay, multiple orthogonal methods\",\n      \"pmids\": [\"37619706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HMGB1 forms a physical complex with SET and HAT1 in lung adenocarcinoma cells (HMGB1/SET/HAT1 complex), inhibiting H3K9 and H3K27 acetylation at the SASH1 locus, thereby suppressing SASH1 expression and facilitating glycolysis and metastasis.\",\n      \"method\": \"Co-immunoprecipitation (HMGB1/SET/HAT1 complex), ChIP (H3K9ace, H3K27ace), Western blot, in vitro and in vivo tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifies complex, ChIP shows histone modification changes at SASH1 locus, single lab\",\n      \"pmids\": [\"37794134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SASH1 interacts with Caskin1/2 via SAM-SAM domain interactions (SASH1 SAM1 domain). This interaction disrupts the Caskin1 tandem SAM homopolymer. Key residues at the end-helix/mid-loop interface mediate this interaction. Structural insights were provided by AlphaFold2-predicted models validated by mutagenesis.\",\n      \"method\": \"Yeast 2-hybrid screening, SEC, ITC, GST pull-down, co-immunoprecipitation, AlphaFold2 structural modeling, mutagenesis, sedimentation assay, TEM, immunofluorescence\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods (Y2H, ITC, GST pulldown, Co-IP), structural modeling with mutagenesis validation, polymer disruption demonstrated by sedimentation/TEM/IF\",\n      \"pmids\": [\"39688081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LATS2 phosphorylates SASH1, forming a MAP4K4-LATS2-SASH1-YAP1 cascade in luminal breast cancer. MAP4K4 negatively regulates LATS2, SASH1, and YAP1 expression and YAP1 phosphorylation. Combined MAP4K4 overexpression and SASH1 silencing promote YAP1 dephosphorylation, YAP1/TAZ nuclear translocation, and downstream transcriptional regulation.\",\n      \"method\": \"Overexpression and siRNA knockdown, phosphorylation assays (LATS2 kinase assay on SASH1), Western blot, nuclear fractionation, in vitro and in vivo tumor models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase phosphorylation assay establishing LATS2→SASH1 modification, epistasis cascade with multiple components, in vivo validation, single lab\",\n      \"pmids\": [\"38657867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SASH1 promotes stem-like characteristics in human melanocytes, and interacts with tankyrase 2 (TNKS2). Multiple assays confirmed SASH1-TNKS2 binding; the SASH1 S519N variant is located in a bona fide tankyrase-binding motif and alters the binding kinetics and affinity of the interaction, impairing SASH1's role in melanocyte stem cell maintenance.\",\n      \"method\": \"Yeast 2-hybrid screening, biochemical binding assays (binding kinetics/affinity), cell-based stem cell assays, SASH1 S519N variant functional analysis\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Y2H plus binding kinetics assays, functional cell assay, preprint status lowers confidence\",\n      \"pmids\": [\"37808724\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SASH1 interacts with TNKS2 (tankyrase 2) via a tankyrase-binding motif; the S519N variant alters binding kinetics and affinity. SASH1 regulates melanocyte stem cell (McSC) maintenance, and this function is TNKS2-dependent. SASH1 S519N is defective in promoting stem-like function.\",\n      \"method\": \"Yeast 2-hybrid screening, biochemical binding affinity assays, clinical examination, human cell assays\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Y2H and biochemical binding assays confirming TNKS2 as SASH1 partner, functional stem cell assay, single lab, peer-reviewed replication of preprint\",\n      \"pmids\": [\"38848986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SASH1 suppresses TGF-β1 signaling through regulation of THBS1. SASH1 knockdown increases TGF-β1 levels, but THBS1 counteracts this increase. SASH1 inhibits proliferation, migration, invasion, EMT, and promotes melanin synthesis through TGF-β1/THBS1 signaling. In vivo, SASH1 knockdown A375 cells show enhanced tumor growth.\",\n      \"method\": \"SASH1/THBS1 modulation by siRNA/overexpression, Western blot/qPCR (SASH1/THBS1/TGF-β1 pathway), cell phenotype assays, melanin synthesis measurement, in vivo xenograft\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — genetic epistasis (SASH1→THBS1→TGF-β1) with rescue experiments, in vivo confirmation, single lab\",\n      \"pmids\": [\"41284354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SASH1 interacts with PKM2 in astrocytes; SASH1 depletion causes increased nuclear accumulation of PKM2, shifts metabolism toward aerobic glycolysis (increased glucose uptake, lactate release, Glut1 and LDHA mRNA expression). A peptide blocking the SASH1-PKM2 interaction reduces astrocytic activation and promotes wound healing in a mouse TBI model.\",\n      \"method\": \"Co-immunoprecipitation (SASH1-PKM2), nuclear fractionation, metabolic assays (glucose uptake, lactate release), qPCR, siRNA knockdown, peptide design, mouse TBI model\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing SASH1-PKM2 interaction, metabolic functional assays, peptide disruption in vivo, single lab\",\n      \"pmids\": [\"41690666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SASH1 inhibits TGF-β1-mediated EMT, cell migration, and invasion in gastric cancer cells, and inhibits phosphorylation of PI3K and Akt in TGF-β1-stimulated cells, placing SASH1 as a negative regulator of the PI3K/Akt pathway downstream of TGF-β1.\",\n      \"method\": \"SASH1 overexpression, Western blot (PI3K/Akt phosphorylation), migration/invasion assays, EMT marker assays\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single overexpression approach, pathway placement by Western blot only\",\n      \"pmids\": [\"27178818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing FAK expression and signaling, as shown by reduced FAK protein levels upon SASH1 overexpression.\",\n      \"method\": \"SASH1 overexpression, Western blot (FAK, MMP-2, MMP-9), MTT assay, Transwell assay\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single overexpression approach, pathway placement by Western blot only without direct binding assay\",\n      \"pmids\": [\"26935246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SASH1 functions as an astrocytic differentiation-maintaining protein. SASH1 knockdown in spinal astrocytes decreases interferon-γ release, increases BDNF release, and reduces GFAP expression. SASH1 expression increases as NSCs differentiate into glial cells; SASH1 depletion maintains higher Nestin levels and increased BDNF in differentiated NSCs. Co-culture of SASH1-knockdown astrocytes with neurons increases axonal growth and TrkB expression in axonal tips.\",\n      \"method\": \"siRNA knockdown in rat astrocytes, ELISA (IFN-γ, BDNF), Western blot (GFAP, Nestin, TrkB), co-culture axonal growth assay, SCI rat model (in vivo siRNA injection, BBB score)\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with defined phenotypic readout plus multiple in vitro mechanistic assays, single lab\",\n      \"pmids\": [\"36286186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SASH1 is required for glial cell migration during embryonic brain development. sash1a morpholino knockdown in zebrafish reduces microglial number in the developing brain and causes abnormal arrangement and disordered orientation of gfap+ glia without affecting motor neuron axonal growth. These phenotypes were rescued by injection of human SASH1 mRNA, confirming functional conservation.\",\n      \"method\": \"Morpholino oligonucleotide knockdown in zebrafish, CRISPR/Cas9 mutagenesis, transgenic zebrafish lines (Tg(gfap:eGFP), Tg(hb9:eGFP), Tg(coro1a:eGFP)), human SASH1 mRNA rescue, behavioral assays\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino and CRISPR knockdown with specific glial phenotype, human mRNA rescue confirming conservation, single lab\",\n      \"pmids\": [\"37741309\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SASH1 is a multifunctional scaffold/adaptor protein containing SH3 and SAM domains that assembles signaling complexes at multiple nodes: it binds TRAF6, TAK1, IKKα/β, and β-arrestin 1 downstream of TLR4 to drive NF-κB/JNK/p38 activation and eNOS-mediated nitric oxide production; interacts with CRKL to inhibit SRC kinase and EMT; is cleaved by caspase-3 during apoptosis, allowing its C-terminal fragment to translocate to the nucleus and activate NF-κB-dependent apoptosis; modulates Hippo signaling through LATS1-dependent phosphorylation at S407 and regulation of YAP/ARHGAP42/actin; interacts with cortactin to regulate actin cytoskeleton and cell-matrix adhesion; suppresses PI3K/Akt, Shh-Gli1, FAK, and TGF-β1/THBS1 pathways; binds Eph receptor SAM domains (notably EphA8) to regulate kinase activity; interacts with TNKS2 to maintain melanocyte stem cells; sequesters PKM2 in astrocytes to regulate glycolysis; and is epigenetically silenced by HMGB1/SET/HAT1-mediated histone deacetylation or direct CpG methylation in cancer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SASH1 is a multidomain SH3/SAM-containing scaffold/adaptor protein that nucleates signaling complexes at the actin cytoskeleton, cell-cell junctions, and inflammatory and growth-control pathways, broadly acting as a tumor-suppressive organizer of adhesion and migration [#1, #2, #8]. In epithelial cells it co-distributes with the actin cytoskeleton and binds cortactin to promote filamentous actin and cell-matrix adhesion while restraining migration, and it localizes to adherens junctions where its loss precipitates a mesenchymal transition [#1, #12]. As a TLR4 scaffold in endothelial cells, SASH1 independently binds TRAF6, TAK1, and IKKα/β, promotes TRAF6/TAK1 ubiquitination, and drives NF-κB/JNK/p38-dependent inflammatory signaling; downstream it engages β-arrestin 1 to activate Akt and eNOS, and Sash1-null mice die perinatally from defective nitric-oxide-dependent alveolar epithelial maturation [#2, #9]. SASH1 suppresses tumor cell invasion through several convergent routes: it binds the oncoprotein CRKL to inhibit SRC kinase and block EMT and metastasis [#8], and it operates within the Hippo pathway as a LATS1/LATS2 substrate (phosphorylated at S407) that restrains YAP and the downstream YAP-ARHGAP42-actin invasion axis [#11, #20]. During UVC-induced apoptosis SASH1 is cleaved by caspase-3, and its C-terminal fragment translocates to the nucleus and chromatin to drive NF-κB-dependent apoptosis [#4]. Through its SAM1 domain SASH1 engages additional partners—Eph receptors (notably EphA8, by a structurally defined SAM-SAM interaction that modulates kinase activity), Caskin1/2 (disrupting their SAM homopolymer), and tankyrase-2 (TNKS2, required for melanocyte stem-cell maintenance)—establishing the SAM domain as a key interaction hub [#15, #17, #19, #22]. SASH1 mutations cause dyschromatosis/dyschromatosis universalis hereditaria with pathological hyperpigmentation through altered melanocyte migration and pigmentation signaling [#3, #14]. In cancer, SASH1 is epigenetically silenced via HMGB1-directed CpG methylation and an HMGB1/SET/HAT1 histone-deacetylation complex at the SASH1 locus [#10, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established SASH1 as a candidate signaling adaptor by identifying its SH3 and SAM domains, framing all subsequent mechanistic work as scaffold biology.\",\n      \"evidence\": \"In silico domain analysis with EST/genomic comparison and Northern blot\",\n      \"pmids\": [\"12771949\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Domain inference only, no functional partner or activity demonstrated\", \"No subcellular localization established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected SASH1 to the actin cytoskeleton, answering what cellular structure it acts on by showing cortactin binding and control of actin-driven adhesion and migration.\",\n      \"evidence\": \"Immunofluorescence co-localization, domain mapping, F-actin staining, adhesion/migration assays with siRNA in epithelial cells\",\n      \"pmids\": [\"21820526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cortactin interaction not validated reciprocally or structurally\", \"Molecular basis of adhesion increase unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined SASH1 as a TLR4 inflammatory scaffold, resolving how it links receptor engagement to NF-κB/MAPK output via direct binding to multiple pathway kinases.\",\n      \"evidence\": \"Reciprocal Co-IP of TRAF6/TAK1/IKKα/β, ubiquitination assays, and pathway/cytokine readouts in LPS-stimulated endothelial cells\",\n      \"pmids\": [\"23776175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and order of complex assembly not defined\", \"Which domain mediates each kinase contact unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked SASH1 mutations to a disease mechanism by showing mutant SASH1 increases melanocyte migration through altered IQGAP1/Gαs binding and E-cadherin loss.\",\n      \"evidence\": \"Patient mutation analysis, Co-IP (IQGAP1, Gαs), migration assays, E-cadherin Western blot\",\n      \"pmids\": [\"23333244\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect binding of IQGAP1/Gαs unresolved\", \"How mutation alters binding mechanistically not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a caspase-regulated nuclear function, showing caspase-3 cleavage generates a C-terminal fragment that drives NF-κB-dependent apoptosis.\",\n      \"evidence\": \"Caspase cleavage assays, cleavage-site mutagenesis, subcellular fractionation, NF-κB inhibitor (DHMEQ) after UVC\",\n      \"pmids\": [\"27831555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear targets of the cleaved fragment not identified\", \"Mechanism of NF-κB activation by the fragment undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed SASH1 upstream of multiple oncogenic kinase/morphogen pathways (Shh-Gli1, PI3K/Akt, FAK) as a suppressor of proliferation and invasion.\",\n      \"evidence\": \"Overexpression with pharmacological agonist rescue, Western blot pathway readouts, xenograft and Transwell assays across hepatocarcinoma, gastric and cervical cancer models\",\n      \"pmids\": [\"28600143\", \"27178818\", \"26935246\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathway placements rely on Western blot/epistasis without direct binding for several\", \"Direct molecular target within each pathway unidentified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed SASH1 governs epithelial lumenogenesis through a DLK1-NOTCH1 axis downstream of CEACAM1.\",\n      \"evidence\": \"RNAi, 3D lumen formation assay, gene array, DLK1 RNAi and γ-secretase epistasis\",\n      \"pmids\": [\"28823832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How SASH1 controls DLK1 expression unknown\", \"No physical interaction defined in this axis\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified CRKL as a direct partner whose SRC activation SASH1 inhibits, providing a defined molecular route by which SASH1 suppresses EMT and metastasis.\",\n      \"evidence\": \"Y2H, Co-IP/MS, domain mapping, dynamic mass redistribution, CRISPR knockout and in vivo metastasis with CRKL-dependent epistasis\",\n      \"pmids\": [\"30480076\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CRKL binding restrains SRC mechanistically not fully resolved\", \"Structural basis of SASH1-CRKL contact undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined an essential developmental role: endothelial SASH1 acts through β-arrestin 1 to drive eNOS/NO signaling that non-autonomously matures alveolar epithelium.\",\n      \"evidence\": \"Global and endothelial-conditional Sash1 knockout mice, Co-IP (β-arrestin 1), eNOS/Akt/cGMP assays, surfactant and histology\",\n      \"pmids\": [\"31067462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between β-arrestin1 and TLR4 kinase complex unresolved\", \"Direct vs indirect eNOS activation mechanism not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established epigenetic silencing of SASH1 via HMGB1-directed CpG methylation, with downstream integrin β8 control of adhesion/migration.\",\n      \"evidence\": \"Methylation assay, ChIP (HMGB1 at SASH1 CpG islands), HMGB1 overexpression, integrin β8 Western blot in astrocytes\",\n      \"pmids\": [\"31138780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methyltransferase recruited by HMGB1 not identified\", \"Direct vs indirect integrin β8 regulation unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Embedded SASH1 in Hippo signaling as both a LATS substrate (S407) and regulator of YAP, defining the YAP-ARHGAP42-actin axis driving invasion.\",\n      \"evidence\": \"Phospho-Western, S407A mutagenesis with rescue failure, YAP/ARHGAP42 epistasis, CAM and xenograft models in TNBC\",\n      \"pmids\": [\"32523092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SASH1 reciprocally promotes LATS1 activity unknown\", \"Functional consequence of S407 phosphorylation on SASH1 structure undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reinforced SASH1's adhesion-maintaining role and characterized melanocyte-pigmentation mechanisms (Mitf, THBS1/TGF-β1) underlying its mutation phenotypes.\",\n      \"evidence\": \"Confocal localization at adherens junctions with RNAi (epithelial cells); Y551D knock-in mice with Mitf IHC; patient-mutation THBS1/TGF-β1 migration assays\",\n      \"pmids\": [\"32586229\", \"32582980\", \"32174800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SASH1 directly binds Mitf complex unproven\", \"Mechanism linking SASH1 to THBS1 transcription unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the first structural insight into the SAM1 domain, showing it is a predominantly disordered monomer distinct from related SAM domains, with a mapped oligomerization region.\",\n      \"evidence\": \"NMR, SEC-MALS, SE-HPLC and D663A/T664K mutagenesis\",\n      \"pmids\": [\"36341956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of monomeric vs oligomeric state in cells unknown\", \"Link between oligomerization and partner binding untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended SASH1's TRAF6-ubiquitination scaffold function to stabilize EZH2 and identified roles in glial differentiation maintenance.\",\n      \"evidence\": \"Co-IP/ubiquitination assays with EZH2 rescue in hemangioma endothelial cells; siRNA in astrocytes with ELISA/Western and co-culture axonal assays\",\n      \"pmids\": [\"35772492\", \"36286186\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How SASH1 promotes TRAF6 ubiquitination toward EZH2 stability unclear\", \"Direct vs indirect control of glial differentiation factors undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established the SAM1 domain as a versatile interaction hub by defining structurally resolved interactions with Eph receptors (EphA8) and Caskin1/2.\",\n      \"evidence\": \"Crystal structure of EphA8-SASH1, Co-IP, kinase assays, cancer mutation analysis; Y2H/ITC/GST pulldown with AlphaFold2 modeling and polymer-disruption assays for Caskin\",\n      \"pmids\": [\"37619706\", \"39688081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequence of SASH1 on EphA8 signaling output beyond kinase assay limited\", \"Physiological context of SASH1-Caskin interaction not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified TNKS2 as a SASH1 partner required for melanocyte stem-cell maintenance, with a disease variant (S519N) in the tankyrase-binding motif impairing this function.\",\n      \"evidence\": \"Y2H, binding kinetics/affinity assays, stem-cell functional assays (preprint then peer-reviewed) with S519N variant analysis\",\n      \"pmids\": [\"37808724\", \"38848986\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream consequence of TNKS2 binding on SASH1 fate unknown\", \"Whether SASH1 is a tankyrase substrate untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated functional conservation of SASH1 in glial migration during brain development using zebrafish with human mRNA rescue.\",\n      \"evidence\": \"sash1a morpholino/CRISPR knockdown, transgenic reporter lines, human SASH1 mRNA rescue\",\n      \"pmids\": [\"37741309\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular pathway driving glial migration phenotype unidentified\", \"Cell-autonomous vs non-autonomous requirement unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended the Hippo connection by identifying a MAP4K4-LATS2-SASH1-YAP1 cascade, with LATS2 directly phosphorylating SASH1.\",\n      \"evidence\": \"LATS2 kinase assay on SASH1, overexpression/siRNA epistasis, nuclear fractionation, tumor models in luminal breast cancer\",\n      \"pmids\": [\"38657867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite(s) targeted by LATS2 not mapped\", \"How SASH1 transmits to YAP1 within the cascade unclear\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed a metabolic role in which SASH1 sequesters PKM2 in astrocytes to restrain glycolysis, with a disrupting peptide promoting TBI wound healing.\",\n      \"evidence\": \"Co-IP (SASH1-PKM2), nuclear fractionation, metabolic assays, peptide disruption in a mouse TBI model\",\n      \"pmids\": [\"41690666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of SASH1-PKM2 interaction undefined\", \"Whether this mechanism operates in other cell types unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SASH1's many partner interactions are coordinated by its SH3 and SAM domains into context-specific complexes, and which domain configurations switch it between adhesion, inflammatory, Hippo, and metabolic functions, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated structural model of full-length SASH1 with multiple partners\", \"Determinants of cell-type-specific partner selection unknown\", \"Post-translational regulation governing function-switching incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 8, 17, 19]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 8, 11, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 4, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1, 12]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 8, 11, 17, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 28]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 12]}\n    ],\n    \"complexes\": [\"TLR4-TRAF6-TAK1-IKK scaffold complex\"],\n    \"partners\": [\"TRAF6\", \"CRKL\", \"ARRB1\", \"LATS1\", \"EPHA8\", \"CASKIN1\", \"TNKS2\", \"PKM2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}